Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.
Hiroji Iwata
Honoraria - Novartis
José Baselga
Consultant or Advisory Role - Novartis
Mario Campone
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Carlos L. Arteaga
No relevant relationships to disclose
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Walter Jonat
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Michelino De Laurentiis
Consultant or Advisory Role - AstraZeneca; Novartis; Roche
Honoraria - AstraZeneca; Novartis; Roche
Eva Ciruelos
No relevant relationships to disclose
Wolfgang Janni
Honoraria - Novartis
Research Funding - Novartis
Thomas Bachelot
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Per Eystein Lonning
No relevant relationships to disclose
Cynthia Ma
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
Ruth O'Regan
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Emmanuelle Di Tomaso
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Bharani Bharani-Dharan
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Vincent Duval
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Helen Lau
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Caroline Germa
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Patrick Urban
Employment or Leadership Position - Novartis
Angelo Di Leo
Consultant or Advisory Role - AstraZeneca; Novartis; Pfizer
Honoraria - AstraZeneca; Novartis; Pfizer
Research Funding - Novartis; Pfizer